The addition of the shark cartilage extract AE-941 (also known as Neovastat) to standard chemoradiotherapy does not improve survival in patients with inoperable stage III non-small-cell lung cancer (NSCLC), according to results of a large multicenter study published online May 26 in the Journal of the National Cancer Institute (JNCI).

The results were first reported at the American Society of Clinical Oncology’s 2007 annual meeting. (See Reuters Health report June 4, 2007: Shark cartilage extract of no benefit in non-small cell lung cancer.)